Cambridge Scores with Genzyme

For those biting their nails over the Vertex move from Cambridge to the Boston Seaport, not to worry. Genzyme has renewed its 82,490 SF lease at 55 Cambridge Parkway, its broker Cassidy Turley FHO announced Monday. The biotech company that develops and manufactures medical therapies for rare ailments like Gaucher?s Disease will stay in this building on the Charles. In the '90s, Genzyme (which was recently acquired by Sanofi) was a pioneer in establishing Cambridge as a global life science cluster. Over the years, Genzyme has continued to expand in the metro area, including newly expanded production plants on the Boston side of the river and in Framingham. Cassidy?s Mike Brown repped Genzyme and Lincoln Property's John Miller  repped the landlord, Invesco.

Continue reading this story with a free account

Log in or register
Sign up for more articles like this
Subscribe to Bisnow's Boston Newsletters
Related Stories

What's At Stake For CRE In Tuesday's U.S. Midterm

From Pandemic Darling To Cautionary Tale: Pickleball Clubs Face A Reckoning After Betting Big On Retail Space

'Distress Is Finally Trading': Investors Chasing Big Discounts On Boston Office

140-Acre Attleboro Golf Course Hits Market, Pitched For Redevelopment

Foundry Robotics Leaves San Francisco For New East Bay HQ

Alexandria Sells Stakes In Megacampuses To Weather Life Sciences Downturn

Nonprofit Developer Buys Mattapan Site For Affordable Housing: The Boston Deal Sheet

Tenant Rep Firm Expands To Philly, Hires Industry Veteran

Downtown Office Tower Sells At Foreclosure Auction For $260M

Data Centers Lose The Top Spot, San Francisco Jumps 40 Places: 9 Takeaways From ULI's 2027 Outlook

JLL Sues Ex-Life Sciences Leader, Alleging Breach Of Noncompete

Cushman & Wakefield, NYC Added To Suit Alleging $250K Agency Lease Shakedown